Trial Profile
A Study to Evaluate the Efficacy and Safety of Boceprevir or Telaprevir With Pegylated Interferon-Alfa and Ribavirin in HIV/HCV Coinfected Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2021
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
- 12 Nov 2016 New trial record